Literature DB >> 36163565

Suspected common bile duct stones: reduction of unnecessary ERCP by pre-procedural imaging and timing of ERCP.

Christina J Sperna Weiland1,2, Evelien C Verschoor3, Alexander C Poen4, Xavier J M N Smeets5, Niels G Venneman6, Abha Bhalla7, Ben J M Witteman8, Hester C Timmerhuis3,9, Devica S Umans3,10, Jeanin E van Hooft11, Marco J Bruno12, P Fockens10, Robert C Verdonk13, Joost P H Drenth14, Erwin J M van Geenen14.   

Abstract

BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) is the procedure of choice to remove sludge/stones from the common bile duct (CBD). In a small but clinically important proportion of patients with suspected choledocholithiasis ERCP is negative. This is undesirable because of ERCP associated morbidity. We aimed to map the diagnostic pathway leading up to ERCP and evaluate ERCP outcome.
METHODS: We established a prospective multicenter cohort of patients with suspected CBD stones. We assessed the determinants that were associated with CBD sludge or stone detection upon ERCP.
RESULTS: We established a cohort of 707 patients with suspected CBD sludge or stones (62% female, median age 59 years). ERCP was negative for CBD sludge or stones in 155 patients (22%). Patients with positive ERCPs frequently had pre-procedural endoscopic ultrasonography (EUS) or magnetic resonance cholangiopancreatography (MRCP) imaging (44% vs. 35%; P = 0.045). The likelihood of ERCP sludge and stones detection was higher when the time interval between EUS or MRCP and ERCP was less than 2 days (odds ratio 2.35; 95% CI 1.25-4.44; P = 0.008; number needed to harm 7.7).
CONCLUSIONS: Even in the current era of society guidelines and use of advanced imaging CBD sludge or stones are absent in one out of five ERCPs performed for suspected CBD stones. The proportion of unnecessary ERCPs is lower in case of pre-procedural EUS or MRCP. A shorter time interval between EUS or MRCP increases the yield of ERCP for suspected CBD stones and should, therefore, preferably be performed within 2 days before ERCP.
© 2022. The Author(s).

Entities:  

Keywords:  Cholangiopancreatography; Cholangiopancreatography magnetic resonance; Choledocholithiasis; Endoscopic retrograde; Gallstones

Year:  2022        PMID: 36163565     DOI: 10.1007/s00464-022-09615-x

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  33 in total

1.  Long term outcome of EUS-based strategy for suspected choledocholithiasis but negative CT finding.

Authors:  Jae Keun Park; Jong Kyun Lee; Ju Il Yang; Keol Lee; Joo Kyung Park; Kwang Hyuck Lee; Kyu Taek Lee
Journal:  Scand J Gastroenterol       Date:  2018-12-05       Impact factor: 2.423

2.  The role of endoscopy in the evaluation of suspected choledocholithiasis.

Authors:  John T Maple; Tamir Ben-Menachem; Michelle A Anderson; Vasundhara Appalaneni; Subhas Banerjee; Brooks D Cash; Laurel Fisher; M Edwyn Harrison; Robert D Fanelli; Norio Fukami; Steven O Ikenberry; Rajeev Jain; Khalid Khan; Mary Lee Krinsky; Laura Strohmeyer; Jason A Dominitz
Journal:  Gastrointest Endosc       Date:  2010-01       Impact factor: 9.427

3.  ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis.

Authors:  James L Buxbaum; Syed M Abbas Fehmi; Shahnaz Sultan; Douglas S Fishman; Bashar J Qumseya; Victoria K Cortessis; Hannah Schilperoort; Lynn Kysh; Lea Matsuoka; Patrick Yachimski; Deepak Agrawal; Suryakanth R Gurudu; Laith H Jamil; Terry L Jue; Mouen A Khashab; Joanna K Law; Jeffrey K Lee; Mariam Naveed; Mandeep S Sawhney; Nirav Thosani; Julie Yang; Sachin B Wani
Journal:  Gastrointest Endosc       Date:  2019-04-09       Impact factor: 9.427

4.  Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline.

Authors:  Gianpiero Manes; Gregorios Paspatis; Lars Aabakken; Andrea Anderloni; Marianna Arvanitakis; Philippe Ah-Soune; Marc Barthet; Dirk Domagk; Jean-Marc Dumonceau; Jean-Francois Gigot; Istvan Hritz; George Karamanolis; Andrea Laghi; Alberto Mariani; Konstantina Paraskeva; Jürgen Pohl; Thierry Ponchon; Fredrik Swahn; Rinze W F Ter Steege; Andrea Tringali; Antonios Vezakis; Earl J Williams; Jeanin E van Hooft
Journal:  Endoscopy       Date:  2019-04-03       Impact factor: 10.093

Review 5.  Adverse events associated with ERCP.

Authors:  Vinay Chandrasekhara; Mouen A Khashab; V Raman Muthusamy; Ruben D Acosta; Deepak Agrawal; David H Bruining; Mohamad A Eloubeidi; Robert D Fanelli; Ashley L Faulx; Suryakanth R Gurudu; Shivangi Kothari; Jenifer R Lightdale; Bashar J Qumseya; Aasma Shaukat; Amy Wang; Sachin B Wani; Julie Yang; John M DeWitt
Journal:  Gastrointest Endosc       Date:  2016-08-18       Impact factor: 9.427

6.  ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

Authors:  Jean-Marc Dumonceau; Christine Kapral; Lars Aabakken; Ioannis S Papanikolaou; Andrea Tringali; Geoffroy Vanbiervliet; Torsten Beyna; Mario Dinis-Ribeiro; Istvan Hritz; Alberto Mariani; Gregorios Paspatis; Franco Radaelli; Sundeep Lakhtakia; Andrew M Veitch; Jeanin E van Hooft
Journal:  Endoscopy       Date:  2019-12-20       Impact factor: 10.093

Review 7.  Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century?

Authors:  Eldon A Shaffer
Journal:  Curr Gastroenterol Rep       Date:  2005-05

8.  Prevalence and ethnic differences in gallbladder disease in the United States.

Authors:  J E Everhart; M Khare; M Hill; K R Maurer
Journal:  Gastroenterology       Date:  1999-09       Impact factor: 22.682

9.  Diagnostic performance of the current risk-stratified approach with computed tomography for suspected choledocholithiasis and its options when negative finding.

Authors:  Hyun Woo Lee; Tae Jun Song; Do Hyun Park; Sang Soo Lee; Dong-Wan Seo; Sung Koo Lee; Myung-Hwan Kim; Jae Hyuck Jun; Ji Eun Moon; Yeon Han Song
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2019-06-18

10.  Incidence of and potential risk factors for gallstone disease in a general population sample.

Authors:  I Halldestam; E Kullman; K Borch
Journal:  Br J Surg       Date:  2009-11       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.